Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clovis Oncology stock logo
CLVS
Clovis Oncology
$0.43
$0.08
$3.32
$11.60M0.248.88 million shs1.16 million shs
Curis, Inc. stock logo
CRIS
Curis
$2.45
-11.6%
$1.94
$1.02
$8.48
$25.63M3.6973,740 shs70,277 shs
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$0.00
$0.00
$1.59
$1K1.534.91 million shsN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$1.71
-6.6%
$1.67
$1.00
$5.01
$15.88M0.5567,061 shs54,620 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00%0.00%0.00%0.00%0.00%
Curis, Inc. stock logo
CRIS
Curis
0.00%+3.38%+22.50%-13.73%-72.16%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00%0.00%0.00%0.00%-99.99%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
0.00%-5.52%-11.86%+6.21%-47.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Curis, Inc. stock logo
CRIS
Curis
2.7809 of 5 stars
3.53.00.00.03.40.01.3
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
3.7339 of 5 stars
3.55.00.00.03.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00
N/AN/AN/A
Curis, Inc. stock logo
CRIS
Curis
3.00
Buy$17.00593.88% Upside
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00
N/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
3.00
Buy$13.25674.85% Upside

Current Analyst Ratings Breakdown

Latest CLVS, CRIS, SABS, and MTEM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Curis, Inc. stock logo
CRIS
Curis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$17.00
5/15/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/14/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/1/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $20.00
4/1/2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
3/31/2025
Curis, Inc. stock logo
CRIS
Curis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $16.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clovis Oncology stock logo
CLVS
Clovis Oncology
$148.76M0.00N/AN/A($2.15) per share0.00
Curis, Inc. stock logo
CRIS
Curis
$11.20M2.29N/AN/A$3.34 per share0.73
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$23.48M0.00N/AN/A$0.78 per share0.00
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$2.24M7.09N/AN/A$6.21 per share0.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clovis Oncology stock logo
CLVS
Clovis Oncology
-$264.52M-$1.83N/AN/AN/A-189.37%N/A-57.78%N/A
Curis, Inc. stock logo
CRIS
Curis
-$47.41M-$6.23N/AN/AN/A-443.35%-923.37%-78.35%7/30/2025 (Estimated)
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$42.19M-$3.70N/AN/AN/A-1,450.14%-94.37%-67.26%8/6/2025 (Estimated)

Latest CLVS, CRIS, SABS, and MTEM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$1.00-$0.56+$0.44-$0.56$0.13 millionN/A
5/6/2025Q1 2025
Curis, Inc. stock logo
CRIS
Curis
-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million
3/31/2025Q4 2024
Curis, Inc. stock logo
CRIS
Curis
-$1.36-$1.25+$0.11-$1.25$2.04 million$2.70 million
3/28/2025Q4 2024
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$1.16-$1.23-$0.07-$1.23$0.12 million$0.05 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/A
Curis, Inc. stock logo
CRIS
Curis
N/AN/AN/AN/AN/A
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A
0.14
0.12
Curis, Inc. stock logo
CRIS
Curis
N/A
1.22
1.22
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/A
1.56
1.56
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
0.09
3.69
3.69

Institutional Ownership

CompanyInstitutional Ownership
Clovis Oncology stock logo
CLVS
Clovis Oncology
24.53%
Curis, Inc. stock logo
CRIS
Curis
29.97%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
95.47%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
7.82%

Insider Ownership

CompanyInsider Ownership
Clovis Oncology stock logo
CLVS
Clovis Oncology
4.40%
Curis, Inc. stock logo
CRIS
Curis
5.70%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
13.90%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
27.77%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A144.96 million138.58 millionOptionable
Curis, Inc. stock logo
CRIS
Curis
6010.46 million7.98 millionNo Data
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
2606.58 million5.67 millionNo Data
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
1409.29 million6.79 millionNot Optionable

Recent News About These Companies

SAB Biotherapeutics price target lowered to $20 from $25 at Chardan
SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum
Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clovis Oncology stock logo

Clovis Oncology NASDAQ:CLVS

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Curis stock logo

Curis NASDAQ:CRIS

$2.45 -0.32 (-11.55%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$2.57 +0.12 (+4.90%)
As of 06/13/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Molecular Templates stock logo

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

SAB Biotherapeutics stock logo

SAB Biotherapeutics NASDAQ:SABS

$1.71 -0.12 (-6.61%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.71 0.00 (-0.23%)
As of 06/13/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.